DecisionDx® DiffDx™-Melanoma is Clinically Validated to Aid Dermatopathologists in Difficult-to-Diagnose Melanocytic Lesions
35-GEP Test Utilization in Lesions of the Head and Neck,
(#WC21 Poster #007)Presented at the American Society of Dermatopathology
57th Annual Meeting
Clinical Validation Study
Estrada, SI, Shackelton, JB, Cleaver, NJ, et al. SKIN: J Cutan Med 2020 4(6), 506-522.
Clinical Validation Poster, (#ASDP20 Poster #296) Presented at the American Society of Dermatopathology 57th Annual Meeting
DiffDx-Melanoma Clinical Utility Studies
Farberg AS, Ahmed KL, Bailey CN, et al. A 35-gene expression profile test for use in suspicious pigmented lesions impacts clinical management decisions of dermatopathologists and dermatologists. SKIN: J Cutan Med 2020 4(6), 523-533.